Telomir Pharmaceuticals (NASDAQ: TELO) announced new research findings from The Ohio State University College of Veterinary Medicine demonstrating that Telomir-Zn produced growth inhibition across human and canine osteosarcoma cell-line models at similar low drug concentrations. The study, conducted under the direction of Shay Bracha, DVM, MS, DACVIM (Oncology), evaluated Telomir-Zn in one human and two canine osteosarcoma models, with the results supporting further translational investigation and a potential development pathway using naturally occurring canine osteosarcoma.
Telomir is in discussions with The Ohio State University College of Veterinary Medicine and assessing next steps for a potential in vivo efficacy study in canine osteosarcoma, which could support both veterinary development and translational advancement toward human osteosarcoma. The company said its immediate focus remains its triple-negative breast cancer program, which is advancing toward site initiation and Phase 1/2 patient enrollment under an active FDA-cleared IND for advanced or metastatic TNBC.
To view the full press release, visit https://nnw.fm/laeGH
About Telomir Pharmaceuticals
Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) is a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic pathways implicated in cancer. The Company’s lead program, Telomir-Zn, is designed to modulate intracellular metal homeostasis and epigenetic regulation and has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration for a Phase 1/2 clinical trial in patients with advanced or metastatic triple-negative breast cancer.
NOTE TO INVESTORS: The latest news and updates relating to TELO are available in the company’s newsroom at https://nnw.fm/TELO
About NetworkNewsWire
NetworkNewsWire (“NNW”) is a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled recognition and brand awareness. NNW is where breaking news, insightful content and actionable information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: https://www.NetworkNewsWire.com/Disclaimer
NetworkNewsWire
Austin, Texas
www.NetworkNewsWire.com
512.354.7000 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is powered by IBN